Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph McGuirk

Showing results (11-20 of 128) with videos related to

Pageof 13
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 17, 2012
Adoptive immunotherapy with CMV-specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infectionsLei Bao, Morton J Cowan, Kimberly Dunham, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|June 21, 2025
Impact of hyperbaric oxygen on post-UCB transplant blood transfusion and growth factor supportHaitham Abdelhakim, Ahmed Hebishy, Leyla Shune, et al.
Current Oncology (Toronto, Ont.)|September 26, 2025
CAR-T Access Disparities for Multiple Myeloma in the Midwest: A Social Determinants of Health PerspectiveMichael Weise, Shebli Atrash, Briha Ansari, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 11, 2002
Increased pulmonary toxicity results from a 1-day versus 2-day schedule of administration of high-dose melphalanLori Williams, Roy A Beveridge, Robert M Rifkin, et al.
Leukemia & Lymphoma|November 4, 2020
Maintenance regimens after a second autologous transplant for multiple myelomaGhulam Rehman Mohyuddin, Maire Okoniewski, Osama Diab, et al.
Molecular Cancer Therapeutics|March 1, 2013
Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cellsWarren Fiskus, Srdan Verstovsek, Taghi Manshouri, et al.
Cytotherapy|July 30, 2017
Building blocks for institutional preparation of CTL019 deliveryJoseph McGuirk, Edmund K Waller, Muna Qayed, et al.
European Journal of Haematology|July 15, 2020
Inpatient mortality of patients with multiple myeloma and renal impairment undergoing autologous stem cell transplantationGhulam Rehman Mohyuddin, Saqib Abbasi, Maire Okoniewski, et al.
Transplantation and Cellular Therapy|April 8, 2021
Clostridioides difficile Infection and Risk of Acute Graft-versus-Host Disease among Allogeneic Hematopoietic Stem Cell Transplantation RecipientsRa'ed Jabr, Wissam El Atrouni, Leyla Shune, et al.
Hematology/Oncology and Stem Cell Therapy|December 14, 2018
Epstein-Barr viremia and post-transplant lymphoproliferative disorders in patients undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamideGhulam Rehman Mohyuddin, John Roller, Leyla Shune, et al.
Pageof 13

Showing results (11-20 of 128) with videos related to

Sort By:
Pageof 13
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 17, 2012
Adoptive immunotherapy with CMV-specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infectionsLei Bao, Morton J Cowan, Kimberly Dunham, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|June 21, 2025
Impact of hyperbaric oxygen on post-UCB transplant blood transfusion and growth factor supportHaitham Abdelhakim, Ahmed Hebishy, Leyla Shune, et al.
Current Oncology (Toronto, Ont.)|September 26, 2025
CAR-T Access Disparities for Multiple Myeloma in the Midwest: A Social Determinants of Health PerspectiveMichael Weise, Shebli Atrash, Briha Ansari, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 11, 2002
Increased pulmonary toxicity results from a 1-day versus 2-day schedule of administration of high-dose melphalanLori Williams, Roy A Beveridge, Robert M Rifkin, et al.
Leukemia & Lymphoma|November 4, 2020
Maintenance regimens after a second autologous transplant for multiple myelomaGhulam Rehman Mohyuddin, Maire Okoniewski, Osama Diab, et al.
Molecular Cancer Therapeutics|March 1, 2013
Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cellsWarren Fiskus, Srdan Verstovsek, Taghi Manshouri, et al.
Cytotherapy|July 30, 2017
Building blocks for institutional preparation of CTL019 deliveryJoseph McGuirk, Edmund K Waller, Muna Qayed, et al.
European Journal of Haematology|July 15, 2020
Inpatient mortality of patients with multiple myeloma and renal impairment undergoing autologous stem cell transplantationGhulam Rehman Mohyuddin, Saqib Abbasi, Maire Okoniewski, et al.
Transplantation and Cellular Therapy|April 8, 2021
Clostridioides difficile Infection and Risk of Acute Graft-versus-Host Disease among Allogeneic Hematopoietic Stem Cell Transplantation RecipientsRa'ed Jabr, Wissam El Atrouni, Leyla Shune, et al.
Hematology/Oncology and Stem Cell Therapy|December 14, 2018
Epstein-Barr viremia and post-transplant lymphoproliferative disorders in patients undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamideGhulam Rehman Mohyuddin, John Roller, Leyla Shune, et al.
Pageof 13